Patient Information

 

Early Observational Data Demonstrated Longer Pancreatic Cancer Patient Survival

Four prestigious MRIdian hospital centers pooled their data after similarly treating a small number of pancreatic cancer patients and found that when using the MRIdian system and applying daily changes, they were able to deliver higher doses of radiation to the tumor, leading to longer overall survival. This promising data was presented just weeks ago at the European Society for Radiotherapy and Oncology (ESTRO) conference, and as a result, ViewRay plans to support a multi-center, prospective clinical trial. Patients diagnosed with pancreatic cancer who are not eligible for surgery will be considered for this study.

More information can be found in this recent press release and additional details will be announced as the study develops:
http://www.viewray.com/press-releases/compelling-early-pancreatic-cancer-data-with-viewray-s-mridian-system-presented-at-estro-36

Pancreas diagram

About Pancreatic Cancer: The American Cancer Society estimates that about 56,670 people in the United States will be diagnosed with pancreatic cancer in 2017 and a staggering amount of those folks, about eighty percent, will die of the disease. Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths.1

1 https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html
Illustration courtesy of the National Institute of Health

 

 
* Required





Subscribe to: Patient Information Newsletter
Copyright 2017 © ViewRay. All rights reserved - KMCreative